Aclaris Therapeutics (FRA:8AT) 3-Year EBITDA Growth Rate : -14.30% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics 3-Year EBITDA Growth Rate?

Aclaris Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.21.

During the past 3 years, the average EBITDA Per Share Growth Rate was -14.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 9.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -3.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aclaris Therapeutics was 23.30% per year. The lowest was -65.90% per year. And the median was 6.00% per year.

Competitive Comparison of Aclaris Therapeutics's 3-Year EBITDA Growth Rate

For the Diagnostics & Research subindustry, Aclaris Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aclaris Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's 3-Year EBITDA Growth Rate falls into.

Aclaris Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Aclaris Therapeutics (FRA:8AT) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Aclaris Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclaris Therapeutics (FRA:8AT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ACRS:USA

Address

640 Lee Road, Suite 200, Wayne, PA, USA, 19087

Website

https://www.aclaristx.com

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics (FRA:8AT) Headlines

No Headlines